Strategic execution · Merger acquisition and divestiture risks
Failure to effectively manage acquisitions, divestitures, strategic investments, restructurings, cost savings initiatives and other portfolio actions may not have the results anticipated. If Corteva is unable to successfully integrate and develop acquired businesses, including its growth in biologicals, Corteva could fail to achieve expected increases in revenues and operating results, as well as anticipated investment returns, synergies and cost savings, which could have a material adverse effect on Corteva's financial results.
Market position and competition · Pricing pressure and margin compression
Additionally, data analytic tools and web-based new direct purchase models offer increased transparency and comparability, which creates price pressures. Corteva cannot predict the pricing or promotional actions of its competitors. Aggressive marketing or pricing by Corteva's competitors could adversely affect Corteva's business, results of operations and financial condition.
Innovation and product development · Intellectual property protection and infringement
Corteva has designed and implemented internal controls to restrict use of, access to and distribution of its intellectual property. Despite these precautions, Corteva's intellectual property is vulnerable to infringement, misappropriation and other unauthorized access, including through employee or licensee error or actions, theft and cybersecurity incidents, and other security breaches.
Innovation and product development · Product development and randd investment risks
New product concepts may be abandoned for many reasons, including greater anticipated development costs, technical difficulties, lack of efficacy, regulatory obstacles or inability to market under regulatory frameworks, competition, inability to prove the original concept, lack of demand and the need to divert focus, from time to time, to other initiatives with perceived opportunities for better returns.
Market position and competition · Disruptive competitors and new market entrants
Many of Corteva's competitors are also making considerable investments in similar new biotechnology products, improved germplasm products, biological and chemical products and agronomic recommendation products.
Market position and competition · Patent expiration and generic competition
Upon the loss or expiration of patent protection for one of Corteva's products or of a product that Corteva licenses, or upon the 'at-risk' launch (despite pending patent infringement litigation against the generic product) by a generic manufacturer of a generic version of one of Corteva's patented products or of a product that Corteva licenses, Corteva can lose a major portion of revenues for that product, which can have a material adverse effect on Corteva's business.
Market position and competition · Industry consolidation and market concentration
Corteva participates in an industry that is highly competitive and has undergone consolidation, which could increase competitive pressures.
Strategic execution · Strategic transformation and turnaround risks
Executing the Proposed Separation will require significant time and attention from Corteva's senior management and employees, which could disrupt Corteva's ongoing business, negatively impact Corteva's relationships with employees, suppliers, customers, distributors, licensors and other stakeholders and adversely affect Corteva's financial results and results of operations.